Entropy Reports 50% Remission in Phase 2 Trial of IV Psilocin Therapy for Binge Eating Disorder
Australian biotechnology company Entropy Neurodynamics (ASX: ENP) has reported encouraging topline results from the first cohort of its Phase 2 ...
Australian biotechnology company Entropy Neurodynamics (ASX: ENP) has reported encouraging topline results from the first cohort of its Phase 2 ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
